Bellicum Pharmaceuticals — Investor Presentation (July 2019)
29 slides from Bellicum Pharmaceuticals's investor presentation, Jul 29, 2019
Slide 1: Investor Presentation
Investor Presentation Striving to deliver cures through controllable cell therapy July 2019
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains estimates, projections and other forward-looking statements, concerning, among other things: our research and development activities relating to our CaspaCIDe® (“iC9”), GoCAR-T ® (incorporating “iMC”) and related technologies; our product candidat
Slide 3: Investment Summary
Investment Summary Rivo-cel GoCAR-T Pipeline Allogeneic polyclonal T-cells for hematologic Controllable CAR-T cells designed to optimize malignancies and inherited blood disorders (+HSCT) efficacy and safety European pediatric opportunity clinically de-risked BPX-601 GoCAR-T promising early clinical
Slide 4: Development Pipeline: Rivo-cel and GoCAR-T
Development Pipeline: Rivo-cel and GoCAR-T Controllable cell therapies that may represent major advances in liquid and solid tumors PRODUCT CANDIDATE DISCOVERY CLINICAL PROOF OF CONCEPT PIVOTAL CLINICAL STATUS Rivo-cel Topline data met primary Rivo-cel iC9 E.U.: Pediatric Leukemias, Lymphomas, and I
Slide 5: Technology Overview
Dp) Bellicum Technology Overview
Slide 6: Most Cell Therapies Only Controlled Before Infusion
Most Cell Therapies Only Controlled Before Infusion Limited ability to expand a narrow therapeutic window Insufficient peak dose Lack of persistence Anergy POOREFFICACY BEFORE INFUSION AFTER INFUSION CONTROLLED UNPREDICTABLE On Target / Off Tumor Collect white Genetic Patient GvHD blood cells modifi
Slide 7: Bellicum Platform Designed to Enable Control After Infusion
Bellicum Platform Designed to Enable Control After Infusion Would provide physicians the ability to expand the therapeutic window in each patient iMC ACTIVATION switch to activate immune cells and modulate the iMC tumor micro- environment Potential for BEFORE INFUSION AFTER INFUSION CONTROLLED CONTR
Slide 8: Chemical Induction of Dimerization (CID) Molecular Switch Platform
Chemical Induction of Dimerization (“CID”) Molecular Switch Platform Rimiducid infusion activates signaling pathways to control T-cell function 1 VECTOR APPLICATION SPECIFIC Monomeric = Dimerized = Viral transduction ACCESSORY PROTEINS 1 Inactive Proteins Active Proteins transfers the DNA 3 from a v
Slide 9: GoCAR-T Pipeline
Dp) Bellicum GoCAR-T Pipeline
Slide 10: GoCAR-T: Differentiated Approach to Cell Therapy
GoCAR-T: Differentiated Approach to Cell Therapy Current Challenges in Cell Therapy GoCAR-T Benefits Limited efficacy in solid tumors Potential for enhanced efficacy in solid tumors via ▪ Inadequate cell proliferation and iMC signaling persistence to sustain efficacy ▪ MyD88 and CD40 are superior co
Slide 11: BPX-601 GoCAR-T Targeting PSCA
BPX-601 GoCAR-T Targeting PSCA Product Summary Unmet Need ▪ Attractive first-in-class solid tumor CAR-T opportunity High unmet need in solid tumors expressing Prostate Stem Cell Antigen (PSCA) ▪ First-in-human experience with iMC Annual Annual % Expressing Incidence ▪ Updated Phase 1 results present
Slide 12: BPX-601: Phase 1 Trial Progression
BPX-601: Phase 1 Trial Progression BP-012 trial in relapsed/refractory pancreatic, gastric, and prostate cancers Dose Full Efficacy Optimized Lead-in Escalation Conditioning Regimen (Cohort 0) (Cohorts 3, 4, 5A) (Cohort 5B) (Cohort 5C) Dose escalation designed conservatively to evaluate safety • Par
Slide 13: BPX-601: No Dose Limiting Toxicities Observed
BPX-601: No Dose Limiting Toxicities Observed Data presented at ASCO 2019 ▪ No dose limiting toxicities were observed Cohort 0 Cohort 3 Cohort 4 Cohort 5A Cohort 5B All Patients Patients, n (%) n = 3 n = 3 n = 3 n = 4 n = 5 N = 18 Any AE 3 (100) 3 (100) 3 (100) 4 (100) 5 (100) 18 (100) ▪ Adverse Eve
Slide 14: BPX-601: iMC-Driven T Cell Expansion & Persistence
BPX-601: iMC-Driven T Cell Expansion & Persistence Flu/Cy Lymphodepletion Results in Increased BPX-601 Cell Expansion and Persistence ▪ Peak expansion 4.9-fold higher in Flu/Cy cohort vs Cy alone cohorts ▪ Persistence improves with: ▪ Administration of rimiducid to activate iMC ▪ Higher cell dose ▪
Slide 15: BPX-601: Evidence of Anti-Tumor Activity
BPX-601: Evidence of Anti-Tumor Activity ▪ 8 (62%) of 13 evaluable patients treated with BPX- 601 and single-dose rim achieved stable disease; 3 had tumor shrinkage of 10-24% ▪ With 9.1 weeks median follow-up (range: 2.9-30.3), median time to next cancer therapy in patients that received subsequent
Slide 16: BPX-601: Clinical Activity and VCN Trends
BPX-601: Clinical Activity and VCN Trends * Indicates subject in Flu/Cy Cohort 5B. Only subjects with >100 days of follow-up included in right panel 15
Slide 17: BPX-603 Dual Switch GoCAR-T Targeting HER2
BPX-603 Dual Switch GoCAR-T Targeting HER2 Product Summary Unmet Need 1 + ▪ HER2 is a validated tumor antigen and is expressed Indication Incidence HER2 5-year OS (Stage IV)1 on numerous solid tumors with high unmet need Gastric 28,000 10-30%3 <20% ▪ Historical HER2 CAR-T studies have shown modest o
Slide 18: Historical HER2 Studies: Modest Clinical Outcomes
Historical HER2 Studies: Modest Clinical Outcomes Study Properties Morgan, 2010 Ahmed, 2015 Feng, 2017 Ahmed, 2017 Hegde, 2019 Construct 4D5-28-BB-z FRP5-28-z Her2-BB-z FRP5-28-z FRP5-28-z Indication(s) Metastatic colon Sarcomas CCA and PCa GBM Sarcomas Patient number 1 19 11 17 10 HER2 expression ≥
Slide 19: BPX-603 Pre-Clinical Studies Demonstrate Potential Clinical Benefits
BPX-603 Pre-Clinical Studies Demonstrate Potential Clinical Benefits Tumor growth Survival 1 0 9 1 0 0 ) C o n tr o l T c e lls r s l / 1 0 8 B P X -6 0 3 + V e h a 2 v 7 5 i m v c B P X -6 0 3 + R im / 7 r s + 1 0 u / s HER2 A549 p ( t 5 0 n e 6 1 0 e c Lung Carcinoma c n r a e i 2 5 5 P 4 d 1 0 (1
Slide 20: RIVO-CEL
Dp) Bellicum RIVO-CEL
Slide 21: Rivo-cel: Opportunity To Transform Treatment Paradigm
Rivo-cel: Opportunity To Transform Treatment Paradigm Current HSCT Treatment paradigm Potential Future HSCT Treatment Paradigm HLA-Matched Toxicity and likelihood MRD Related Donor (MRD) of match Alternative Alternative Alternative HLA-Matched Unrelated Donor (MUD) Alternative rivo-cel MUD + Other D
Slide 22: BP-004 Study: Basis for European Pediatric Approval
BP-004 Study: Basis for European Pediatric Approval Phase 1/2 study of rivo-cel in pediatric patients following TCR 훼β depleted allo-HSCT High risk pediatric αβ T-cell and B-cell Rimiducid for patients who malignancies and non- depleted haplo-HSCT Rivo-cel develop visceral GvHD or are malignant diso
Slide 23: Rivo-cel Met Primary Endpoint for EU Registrational Clinical Trial BP-004
Rivo-cel Met Primary Endpoint for EU Registrational Clinical Trial BP-004 1 All pre-specified key secondary endpoints also demonstrated non-inferiority ▪ Primary endpoint of non-inferiority for event free survival (EFS) at 180 days of 90.9% (95% CI: 84.8, 94.6) achieved for patients receiving haplo-
Slide 24: Rivo-cel: High Rates of Disease-Free and Overall Survival
Rivo-cel: High Rates of Disease-Free and Overall Survival Interim survival results1 With median follow-up of N= 166, Events = 9, Overall Survival 94.4% 20.3 months (0.5 – 47.4 (95% CI 90.8-98%) months): ▪ Relapse-free survival 82.9% in malignant patients ▪ Disease-free survival 95.2% in non- maligna
Slide 25: Rivo-cel: High Rates of GvHD Response to Rimiducid
Rivo-cel: High Rates of GvHD Response to Rimiducid Interim results1 of response in patients refractory to standard of care treatment Methods & Evaluable Population Efficacy Results Translational Results Patients who developed visceral Best overall response of 70% Reduction in rivo-cel serum levels G
Slide 26: Rivo-cel Addresses Key Shortcomings
Rivo-cel Addresses Key Shortcomings Rivo-cel addresses shortcomings of stem cell transplants to treat hematological malignancies and inherited blood disorders Rivo-cel Target Market Matched Related Matched Unrelated Haplo and Rivo-cel Donor (MRD) Donor (MUD) Other +HSCT % of Current Market 25-30% ~5
Slide 27: Rivo-cel: Significant Market Opportunity
Rivo-cel: Significant Market Opportunity Potential List Price Patient Population Market Opportunity Additional Opportunities Haplo/ European Initial market: Other: EU Pediatric* 0.4 Pediatric Cost (in thousands) Effectiveness $0.5-0.7 ▪ Geographic expansion TOTAL: 1.8 Analysis MUD: 1.4 billion ▪ U.S
Slide 28: Anticipated 2H'19 and 2020 Key Program Milestones
Anticipated 2H’19 and 2020 Key Program Milestones Milestone Timing Presentation of updated Phase 1 results with repeat Q4’19 / Q1’20 BPX-601 rimiducid dosing Updated Phase 1 and Phase 2 results 2020 IND clearance for BPX-603 2H’19 CAR-T IND submission for BPX-802 Late 2019 PIPELINE BPX-603 Phase 1 d
Slide 29: Investment Summary
Investment Summary Rivo-cel GoCAR-T Pipeline Allogeneic polyclonal T-cells for hematologic Controllable CAR-T cells designed to optimize malignancies and inherited blood disorders (+HSCT) efficacy and safety European pediatric opportunity clinically de-risked BPX-601 GoCAR-T promising early clinical
Bellicum Pharmaceuticals — Investor Presentation (July 2019) on 6ix